Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana

被引:32
|
作者
Mwita, Julius C. [1 ,2 ]
Francis, Joel M. [3 ]
Oyekunle, Anthony A. [1 ,2 ]
Gaenamong, Marea [2 ]
Goepamang, Monkgogi [2 ]
Magafu, Mgaywa G. M. D. [4 ]
机构
[1] Univ Botswana, Dept Internal Med, Fac Med, Gaborone, Botswana
[2] Princess Marina Hosp, Dept Internal Med, Gaborone, Botswana
[3] Natl Inst Med Res, Muhimbili Ctr, Dar Es Salaam, Tanzania
[4] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
关键词
warfarin; quality; anticoagulation control; Botswana; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; DABIGATRAN; THERAPY; STROKE; RISK; DETERMINANTS; ASSOCIATION; INTENSITY; DISEASE;
D O I
10.1177/1076029617747413
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Warfarin treatment requires regular and proper monitoring to avoid overanticoagulation and at the same time to prevent thromboembolic complications. This study assessed the quality of warfarin anticoagulation at Princess Marina Hospital in Botswana. This cross-sectional study consecutively enrolled patients who were on warfarin for at least 3 months in the outpatient medical clinic. The level of anticoagulation was determined by the time in therapeutic range (TTR) using the Rosendaal method that calculates the percentage of days when the international normalized ratio is in the therapeutic range (2.0-3.0). Poor anticoagulation control was defined as an estimated TTR <65%. We performed univariate and multivariate logistic regression to assess predictors of poor anticoagulation control. Of total, 410 (68.8% women) patients whose median age was 46 (interquartile range [IQR], 35-58) years were enrolled. Indications for warfarin included mechanical heart valves, 185 (45.1%); deep vein thrombosis, 114 (26.8%); and atrial fibrillation, 68 (17.8%). Of the 2004 tests (an average of 4.9 tests per patient) assessed, only 20% of the tests were within the therapeutic range. The median TTR was 30.8% (IQR, 15.2-52.7). Most (85.1%) patients had poor anticoagulation control. Cigarette smoking and pulmonary hypertension perfectly predicted poor anticoagulation. Hypertension was a predictor of poor anticoagulation control (adjusted odds ratio = 2.24; 95% confidence interval: 1.02-4.94). The quality of anticoagulant therapy with warfarin in Botswana patients is poor. The evidence calls for efforts to improve the level of anticoagulation control among patients on warfarin in Botswana.
引用
收藏
页码:596 / 601
页数:6
相关论文
共 50 条
  • [21] The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients
    Poli, Daniela
    Antonucci, Emilia
    Marcucci, Rossella
    Mannini, Lucia
    Falciani, Michela
    Abbate, Rosanna
    Gensini, Gian Franco
    Prisco, Domenico
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 132 (01) : 109 - 113
  • [22] Profiles of patients on warfarin anticoagulation therapy in a leading tertiary referral hospital in Kenya; findings and implications for Kenya
    Nyamu, David Gitonga
    Guantai, Anastasia Nkatha
    Osanjo, George Oyamo
    Godman, Brian
    Aklillu, Eleni
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (03) : 165 - 173
  • [23] Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries An Analysis of Patients Receiving Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial
    Van Spall, Harriette G. C.
    Wallentin, Lars
    Yusuf, Salim
    Eikelboom, John W.
    Nieuwlaat, Robby
    Yang, Sean
    Kabali, Conrad
    Reilly, Paul A.
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    CIRCULATION, 2012, 126 (19) : 2309 - 2316
  • [24] Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study
    Chitsike, R. S.
    Rodger, M. A.
    Kovacs, M. J.
    Betancourt, M. T.
    Wells, P. S.
    Anderson, D. R.
    Chagnon, I.
    Le Gal, G.
    Solymoss, S.
    Crowther, M. A.
    Perrier, A.
    White, R. H.
    Vickars, L. M.
    Ramsay, T.
    Kahn, S. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) : 2039 - 2044
  • [25] Warfarin adherence and anticoagulation control in atrial fibrillation patients: a systematic review
    Ababneh, M.
    Nasser, S. A.
    Rababa'h, A.
    Ababneh, F.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7926 - 7933
  • [26] Assessment of an Intervention to Reduce Aspirin Prescribing for Patients Receiving Warfarin for Anticoagulation
    Schaefer, Jordan K.
    Errickson, Josh
    Gu, Xiaokui
    Alexandris-Souphis, Tina
    Ali, Mona A.
    Haymart, Brian
    Kaatz, Scott
    Kline-Rogers, Eva
    Kozlowski, Jay H.
    Krol, Gregory D.
    Shah, Vinay
    Sood, Suman L.
    Froehlich, James B.
    Barnes, Geoffrey D.
    JAMA NETWORK OPEN, 2022, 5 (09)
  • [27] Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia
    Jonkman, Lauren J.
    Gwanyanya, Marvelous P.
    Kakololo, Monika N.
    Verbeeck, Roger K.
    Singu, Bonifasius S.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (07) : 341 - 346
  • [28] Who Will Achieve Stable Anticoagulation Therapy With Warfarin?
    An, Yoshimori
    Akao, Masaharu
    CIRCULATION JOURNAL, 2018, 82 (01) : 17 - 18
  • [29] Intensity and Quality of Warfarin Anticoagulation in Chinese Patients Setting the Record Straight
    Eikelboom, John W.
    Hart, Robert G.
    STROKE, 2015, 46 (01) : 5 - 6
  • [30] Predictors of hospital mortality and serious complications in patients admitted with excessive warfarin anticoagulation
    Pourafkari, Leili
    Ghaffari, Samad
    Khaki, Nasrin
    Hobika, Geoffrey H.
    Masnadi-Shirazi, Kourosh
    Nader, Nader D.
    THROMBOSIS RESEARCH, 2016, 137 : 79 - 84